SCHEMBL5202587

SCHEMBL5202587

CC[C@H](C)[C@H](N)C(=O)N1CC[C@H](O)[C@@H]1C#N

nearest known ligand 0.62

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 19/20 0.62
DPP8 Q6V1X1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5206600 0.79 DPP4 (0.65) DPP4DPP8
SCHEMBL3223828 0.79 DPP4 (0.59) DPP4DPP8
SCHEMBL6238520 0.77 DPP4 (1.00) DPP4DPP8
SCHEMBL6238524 0.77 DPP4 (1.00) DPP4DPP8
SCHEMBL5647935 0.77 DPP4 (1.00) DPP4DPP8
SCHEMBL5647937 0.77 DPP4 (1.00) DPP4DPP8
SCHEMBL14656008 0.76 DPP4 (0.61) DPP4DPP8
SCHEMBL14655953 0.76 DPP4 (0.61) DPP4DPP8
Hydrochloric Acid SCHEMBL5652236 0.76 DPP4 (0.97) DPP4DPP8
SCHEMBL15492419 0.76 DPP4 (0.58) DPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070112059-A1 CYANOPYRROLIDINE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. 2007-05-17 US disclosed
US-20070112205-A1 CYANOPYRROLIDINE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. 2007-05-17 US disclosed
EP-1746086-A1 Cyanopyrrolidine derivatives TAISHO PHARMACEUTICAL CO., LTD (JP) 2007-01-24 EP disclosed
US-20040072892-A1 Cyanopyrrolidine derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 US disclosed
EP-1333025-A1 CYANOPYRROLIDINE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD (JP) 2003-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072892-A1 Cyanopyrrolidine derivatives CCR9, OPRD1, CBR1 DPP4 2412/4885DPP8 2730/4885
US-20070112059-A1 CYANOPYRROLIDINE DERIVATIVES DPP4, DPP9, DPP3 DPP4 1/4885DPP8 7/4885
US-20070112205-A1 CYANOPYRROLIDINE DERIVATIVES CBR3, CBR1, TERT DPP4 3721/4885DPP8 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.